ImmuCell shifts focus to First Defense after FDA letter on Re-Tain. Sales force up by 50%, manufacturing expands.
In Portland, Maine on December 24, 2025, ImmuCell Corporation (Nasdaq: ICCC) disclosed receiving an Incomplete Letter from the FDA on December 23, 2025 regarding its Re-Tain ® New Animal Drug Application. Additionally, the company shared plans to augment its First Defense ® field sales team by 50% and enhance its First Defense ® manufacturing capacity. The move comes as ImmuCell focuses on developing, producing, and promoting products that enhance cattle well-being and effectiveness.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments